Drs Peter Salgo, John L. Fox, Ira M. Klein, Michael Kolodziej, Bryan Loy, Irwin W. Tischler, and Christopher Sweeney discuss the high costs associated with oncology drugs and explain how clinical pathway are being implemented to manage drug utilization and incentivize providers.
Drs Loy and Kolodziej explain when considering and developing a clinical pathway, together providers and payers evaluate the clinical efficacy, tolerability/side effect profile, and cost effectiveness of treatments.
Although most pathways are based on evidence, various factors may still make providers unable to resistant to utilizing a specific from utilizing a specific algorithm when treating patients in their practice, comment Drs Tischler and Klein. Dr Tischler notes that if a provider is against utilizing the suggested pathway, there is little that can change his or her thinking. Dr Klein adds that if the provider chooses not to adhere to the pathway, payers may not reimburse for the treatment. Where there may be a dearth of clinical evidence, Dr Sweeney stresses the utility of consensus guidelines in providing optimal care for each cancer patient.
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
A new study highlights significant disparity in reimbursement rates across states between hospitals and Medicare; the first patient to receive a genetically modified pig kidney has died; research examines outcomes of over 500 patients receiving medication abortion pills by mail.
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Looking Back on ISPOR 2024: Hot Policy Topics, Welcome Focus on Employers, and More
May 10th 2024Kimberly Westrich, MA, chief strategy officer of the National Pharmaceutical Council, reflects on the most valuable learnings from the 2024 meeting of ISPOR—The Professional Society for Health Economics and Outcomes Research, including lively discussions of the Inflation Reduction Act and workshops on value assessment.
Read More